Certara (CERT, Financial) has seen its price target raised by Baird analyst Joe Vruwink, who updated the firm's projections in light of recent developments. The price target was increased from $9 to $13, while the analyst maintains a Neutral rating on the stock.
This adjustment comes as the FDA has shown strong support for Biosimulation, which is a key component of Certara's offerings. The FDA's endorsement has encouraged a reevaluation of Certara's market potential and revenue prospects, prompting the update in the firm's model.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 9 analysts, the average target price for Certara Inc (CERT, Financial) is $14.11 with a high estimate of $17.00 and a low estimate of $11.00. The average target implies an upside of 34.26% from the current price of $10.51. More detailed estimate data can be found on the Certara Inc (CERT) Forecast page.
Based on the consensus recommendation from 11 brokerage firms, Certara Inc's (CERT, Financial) average brokerage recommendation is currently 2.5, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Certara Inc (CERT, Financial) in one year is $20.66, suggesting a upside of 96.57% from the current price of $10.51. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Certara Inc (CERT) Summary page.
